IV chelation therapy is a medical treatment in which a synthetic solution is infused into the bloodstream to bind heavy metals and remove them from the body. The most commonly used agent is a compound called EDTA (ethylenediaminetetraacetic acid), which was first approved for treating lead poisoning in 1953. While chelation has clear, FDA-approved uses for metal poisoning, it’s also marketed for heart disease, autism, and other conditions where the evidence is weak or nonexistent.
How Chelation Works in the Body
Chelating agents contain molecules rich in oxygen that donate electrons and latch onto metal ions circulating in your blood. Once a chelating molecule binds to a metal like lead, mercury, or arsenic, it forms a stable complex that’s water-soluble and too tightly bonded for the metal to cause further damage. Your kidneys then filter these complexes out, and you excrete them in urine, often within hours of the infusion.
EDTA, the agent used most often in IV chelation, passes through the body largely unmetabolized. It goes in, grabs metals, and comes out in essentially the same chemical form. Early versions used a pure sodium form of EDTA, but this pulled calcium out of the bloodstream along with toxic metals, causing dangerous drops in calcium levels. Modern formulations use a calcium-bonded version. When this version encounters a metal like lead, the calcium gets displaced and the lead takes its place, reducing the risk of calcium depletion.
FDA-Approved Uses
The FDA has approved different chelating agents for specific types of metal poisoning, each matched to the metal it removes most effectively:
- Lead poisoning: Calcium EDTA (IV) and succimer/DMSA (oral, approved for children with blood lead levels above 45 micrograms per deciliter)
- Arsenic, gold, and mercury poisoning: A chelator called dimercaprol, sometimes combined with calcium EDTA for acute lead cases
- Iron overload: Deferoxamine (IV), approved for acute iron poisoning and chronic iron buildup from repeated blood transfusions in conditions like thalassemia
- Copper storage disease (Wilson’s disease): Penicillamine (oral)
- Radioactive contamination: DTPA agents, approved in 2004 to help eliminate plutonium, americium, or curium
These are the conditions where the benefit of chelation is well established. Outside of them, the picture gets much murkier.
The Heart Disease Question
For decades, some practitioners have promoted IV EDTA chelation as a treatment for cardiovascular disease, claiming it can clear clogged arteries, lower blood pressure, and serve as an alternative to bypass surgery. The theory is that EDTA strips calcium from arterial plaque, breaking it down. This idea led to a major federally funded clinical trial.
The Trial to Assess Chelation Therapy (TACT), published in 2013, studied patients who had already suffered a heart attack. It found an 18% relative reduction in a composite of cardiovascular events (death, heart attack, stroke, hospitalization for chest pain, or the need for a heart procedure). The result was modest and drew particular interest because it appeared stronger in patients with diabetes.
That finding prompted TACT2, a larger follow-up trial focused specifically on diabetic patients over age 50 who had previously had a heart attack. The results, published in 2024, were disappointing. Among 959 participants followed for a median of four years, 35.6% of those receiving chelation experienced a major cardiovascular event compared to 35.7% in the placebo group. The difference was statistically meaningless. Five-year event rates were nearly identical: 45.8% for chelation versus 46.5% for placebo.
In short, the best available evidence does not support IV chelation as a heart disease treatment. No major cardiology guidelines recommend it.
Unapproved and Unproven Uses
The FDA has issued direct warnings about companies marketing over-the-counter chelation products for conditions including autism spectrum disorders, Alzheimer’s disease, Parkinson’s disease, high cholesterol, and complications of diabetes. These products have no demonstrated benefit for any of these conditions.
The agency’s concern is twofold. First, people may delay proven treatments for serious diseases while relying on chelation. Second, chelation itself carries real risks, including dehydration, kidney failure, and in rare cases, death. These are not theoretical concerns. They apply even to prescription chelation agents used under medical supervision, let alone unregulated OTC products.
What a Treatment Session Looks Like
A single IV chelation session typically takes about three hours. You sit in a chair while the solution drips slowly into a vein, similar to receiving any other IV infusion. For heavy metal poisoning, the number of sessions depends on how much metal is in your body and how quickly your levels drop. Protocols for cardiovascular claims have historically involved 10 to 30 infusions spread over several months.
Each session costs roughly $75 to $125. A full course of 20 to 30 treatments can exceed $5,000. Insurance generally covers chelation when it’s prescribed for FDA-approved indications like lead poisoning or iron overload, but it typically does not cover it for cardiovascular disease or other unapproved uses.
Side Effects and Risks
Common side effects of IV EDTA chelation include fatigue, headache, nausea, fever, and pain at the injection site. Some people experience a drop in blood pressure during or after the infusion, along with increased urinary frequency as the kidneys work to excrete the chelate-metal complexes.
The serious risks are more concerning. Kidney damage is the most significant, because the kidneys bear the entire burden of filtering out the chelated metals. Kidney toxicity from EDTA is dose-dependent and usually reversible if treatment stops, but exceeding the maximum daily dose of 75 milligrams per kilogram of body weight can be fatal. Dangerous drops in calcium can still occur, potentially causing muscle spasms, irregular heart rhythms, or seizures. Bone marrow suppression, prolonged bleeding time, and respiratory arrest have also been reported, though these are rare.
Chelation also strips essential minerals from the body alongside the toxic ones. Zinc, copper, selenium, and calcium can all be depleted during treatment. This is why medical protocols call for regular blood work: kidney function markers checked every one to three months, and mineral levels monitored at least annually throughout the course of treatment. A baseline hearing test is also standard before starting chelation, since hearing loss is a recognized sign of chelator toxicity.
Different Chelating Agents for Different Metals
Not all chelators work the same way or target the same metals. EDTA is the go-to for lead, but research suggests that DMSA (an oral agent) may be a better first choice for moderate lead poisoning because it causes fewer side effects. For mercury poisoning, both DMPS and DMSA show promise, while DMPS appears more effective against arsenic. Deferoxamine remains the standard IV option for iron overload, though oral alternatives exist for long-term management.
The choice of agent, route (IV versus oral), and treatment duration all depend on which metal is involved, how severe the exposure is, and how well your kidneys are functioning. This is not a one-size-fits-all therapy, which is part of why unsupervised or over-the-counter chelation is risky. Using the wrong agent, or chelating when there’s no confirmed metal burden, means you’re taking on the side effects without any potential benefit.